Virologica Sinica

, Volume 34, Issue 3, pp 334–337 | Cite as

Identification of a Novel Universal Potential Epitope on the Cytoplasmic Tail of H7N9 Virus Hemagglutinin

  • Xi Liu
  • Li Ding
  • Jing Yuan
  • Jian Liao
  • Lian Duan
  • Wenfei Wang
  • Weiguo Tan
  • Weiye Yu
  • Boping Zhou
  • Xinchun Chen
  • Zheng YangEmail author

Dear Editor,

H7N9 is a recently identified subtype of influenza A virus that caused a major outbreak in humans in China in 2013. According to the latest data provided by the Chinese Center for Disease Control and Prevention (, updated on October 31, 2018), the mortality rate of H7N9 infections in China amounts to 39.7% (611/1536). Thus, H7N9 poses a serious public health threat.

Influenza A viruses comprise a group of antigenically diverse pathogens that cause respiratory tract infections in both animal and human populations (Thornburg et al.2016). Subtypes of influenza A viruses are characterized by their surface glycoproteins, including hemagglutinin (HA) and neuraminidase (NA). HA consists of a globular head region with a receptor-binding pocket and a conserved stem motif (Liu et al.2016), and mediates the binding of influenza A virus to host cells (Melikyan et al.1999). After binding, HA can be divided into three domains: an...



This study was funded by the National Natural Science Foundation of China (#31500719 (Zheng Yang) and #81672027 (Boping Zhou)), the Science and Technology Grant of Shenzhen (#JCYJ20160427151500192 (Jing Yuan), #JCYJ20150402111430643 (Zheng Yang), and #JSGG20140701164558078 (Boping Zhou)), the Science and Technology Project of Zhuhai (#20161027E030031 (Xi Liu)) and the Medical Science and Technology Research Fund of Guangdong (#A2017037 (Xi Liu)).

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Animal and Human Rights Statement

The study was approved by the ethics committees of Shenzhen Third People’s Hospital. All participants provided written informed consent. Written consents were obtained from all patients or their authorizers involved in the study.


  1. Carrat F, Flahault A (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25:6852–6862CrossRefGoogle Scholar
  2. Chen J, Kovacs JM, Peng H, Rits-Volloch S, Lu J, Park D, Zablowsky E, Seaman MS, Chen B (2015) HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science 349:191–195CrossRefGoogle Scholar
  3. Deng L, Cho KJ, Fiers W, Saelens X (2015) M2e-based universal influenza A vaccines. Vaccines (Basel) 3:105–136CrossRefGoogle Scholar
  4. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin Ö, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH (2012) Highly conserved protective epitopes on influenza B viruses. Science 337:1343–1348CrossRefGoogle Scholar
  5. Gerhard W, Mozdzanowska K, Zharikova D (2006) Prospects for universal influenza virus vaccine. Emerg Infect Dis 12:569–574CrossRefGoogle Scholar
  6. Imai M, Watanabe S, Kawaoka Y (2012) The cytoplasmic tail domain of influenza B virus hemagglutinin is important for its incorporation into virions but is not essential for virus replication in cell culture in the presence of compensatory mutations. J Virol 86:11633–11644CrossRefGoogle Scholar
  7. Lee AC, Zhu H, Zhang AJ, Li C, Wang P, Li C, Chen H, Hung IF, To KK, Yuen KY (2015) Suboptimal humoral immune response against influenza A(H7N9) virus is related to its internal genes. Clin Vaccine Immunol 22:1235–1243CrossRefGoogle Scholar
  8. Liu WC, Jan JT, Huang YJ, Chen TH, Wu SC (2016) Unmasking stem-specific neutralizing epitopes by abolishing N-linked glycosylation sites of influenza virus hemagglutinin proteins for vaccine design. J Virol 90:8496–8508CrossRefGoogle Scholar
  9. Melikyan GB, Lin S, Roth MG, Cohen FS (1999) Amino acid sequence requirements of the transmembrane and cytoplasmic domains of influenza virus hemagglutinin for viable membrane fusion. Mol Biol Cell 10:1821–1836CrossRefGoogle Scholar
  10. Scolari S, Imkeller K, Jolmes F, Veit M, Herrmann A, Schwarzer R (2016) Modulation of cell surface transport and lipid raft localization by the cytoplasmic tail of the influenza virus hemagglutinin. Cell Microbiol 18:125–136CrossRefGoogle Scholar
  11. Shcherbinin DN, Alekseeva SV, Shmarov MM, Smirnov YA, Naroditskiy BS, Gintsburg AL (2016) The analysis of B-cell epitopes of influenza virus hemagglutinin. Acta Nat 8:13–20CrossRefGoogle Scholar
  12. Siche S, Brett K, Moller L, Kordyukova LV, Mintaev RR, Alexeevski AV, Veit M (2015) Two cytoplasmic acylation sites and an adjacent hydrophobic residue, but no other conserved amino acids in the cytoplasmic tail of ha from influenza A virus are crucial for virus replication. Viruses 7:6458–6475CrossRefGoogle Scholar
  13. Thornburg NJ, Zhang H, Bangaru S, Sapparapu G, Kose N, Lampley RM, Bombardi RG, Yu Y, Graham S, Branchizio A, Yoder SM, Rock MT, Creech CB, Edwards KM, Lee D, Li S, Wilson IA, García-Sastre A, Albrecht RA, Crowe JE Jr (2016) H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. J Clin Invest 126:1482–1494CrossRefGoogle Scholar
  14. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX, Harrison SC (2011) Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA 108:14216–14221CrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS 2019

Authors and Affiliations

  1. 1.Department of Infectious Diseases, The Fifth Affiliated HospitalSun Yat-sen UniversityZhuhaiChina
  2. 2.Lab for Tuberculosis ResearchShenzhen Center for Chronic Disease ControlShenzhenChina
  3. 3.Department of Infectious DiseasesThe Third People’s Hospital of Shenzhen (The Second Affiliated Hospital of Southern University of Science and Technology)ShenzhenChina
  4. 4.Shenzhen Key Laboratory of Infection and ImmunityThe Third People’s Hospital of Shenzhen (The Second Affiliated Hospital of Southern University of Science and Technology)ShenzhenChina
  5. 5.Department of Pathogen Biology, School of MedicineShenzhen UniversityShenzhenChina
  6. 6.Longhua Branch of Shenzhen People’s HospitalShenzhenChina

Personalised recommendations